KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Convertible Debt for 4 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt fell 1.64% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Dec 2025, down 1.64%, and an annual FY2025 reading of $1.0 billion, down 1.64% over the prior year.
  • Convertible Debt was $1.0 billion for Q4 2025 at Alnylam Pharmaceuticals, down from $1.0 billion in the prior quarter.
  • Across five years, Convertible Debt topped out at $1.0 billion in Q3 2025 and bottomed at $1.0 billion in Q4 2025.
  • Average Convertible Debt over 4 years is $1.0 billion, with a median of $1.0 billion recorded in 2023.
  • Peak annual rise in Convertible Debt hit 1.62% in 2025, while the deepest fall reached 1.64% in 2025.
  • Year by year, Convertible Debt stood at $1.0 billion in 2022, then grew by 0.38% to $1.0 billion in 2023, then increased by 0.38% to $1.0 billion in 2024, then fell by 1.64% to $1.0 billion in 2025.
  • Business Quant data shows Convertible Debt for ALNY at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.